A look back at the biggest stories this week in biotech and what they mean for investors.
Market-trouncing returns could be written in this 5-Star.
Can VIVUS's Qsymia Become a Billion Dollar Medication?
Is this meaningful? Or just another movement?
Qsymia made it to the market this year and met a tepid reaction. What's next?
Market-trouncing returns could be written in these five stars.
Keeping your portfolio healthy.
Affymax's drug treating anemia in dialysis patients was FDA approved this year, and is now a major threat to the competition. That has shares up nearly 270% for the year, making Affymax #11 on our list of the very best healthcare stocks of 2012.
A yearly review of what worked and what didn't in the hospital sector, as well as one company to keep your eyes on next year.
Short-term uncertainty doesn't impact this insurer’s long-term appeal.